Literature DB >> 21987939

A study of the use of Primolut N tablet as a contraceptive in the Kumasi metropolis of Ghana.

Henry S Opare-Addo1, Patrick K Britwum, George A O Ampong.   

Abstract

This study investigated the use of Primolut N tablet which contains norethisterone 5mg popularly called N-tablet by users as a pre-coital contraceptive by women in the Kumasi metropolis of Ghana. Clients who called at any of the twenty (20) selected Pharmacies in residential areas within the Kumasi metropolis demanding the drug, with or without valid prescriptions were interviewed using a guide. Of the two hundred and twenty (220) users interviewed, 94% demanded the drug for contraception and 6% for menstrual disorders. Sixty one percent of those demanding it for contraception were between the ages 20-25 years. Respondents preferred the use of norethisterone tablets as a contraceptive to other methods because it worked for them and they also found it easy and convenient taking a tablet just before coitus than taking daily oral contraceptive pills. Norethisterone is being used as a pre-coital contraceptive, though the efficacy, safety and reliability of the drug for that purpose is unknown. Until these are known, women must be discouraged from using the drug.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21987939

Source DB:  PubMed          Journal:  Afr J Reprod Health        ISSN: 1118-4841


  2 in total

1.  Use of non-emergency contraceptive pills and concoctions as emergency contraception among Nigerian University students: results of a qualitative study.

Authors:  Anthony Idowu Ajayi; Ezebunwa Ethelbert Nwokocha; Wilson Akpan; Oladele Vincent Adeniyi
Journal:  BMC Public Health       Date:  2016-10-04       Impact factor: 3.295

2.  Contraceptive and abortion practices of young Ghanaian women aged 15-24: evidence from a nationally representative survey.

Authors:  Sarah C Keogh; Easmon Otupiri; Philicia W Castillo; Naomi W Li; Joana Apenkwa; Chelsea B Polis
Journal:  Reprod Health       Date:  2021-07-18       Impact factor: 3.223

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.